U.S. health officials have paused the distribution of two Eli Lilly & Co.
LLY,
-1.18%

Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.

The Department of Health and Human Services said Friday that it is immediately pausing all distribution of bamlanivimab and etesevimab together, as well as etesevimab alone to be paired with existing supplies of bamlanivimab, in the U.S. until further notice.

An expanded version of this article appears on WSJ.com.

Popular stories from WSJ.com:



Source link

×